The host microbiome and impact of tuberculosis chemotherapy
The treatment of Mycobacterium tuberculosis infection is often viewed in isolation from other human microbial symbionts. Understandably, the clinical priority is eliminating active or latent tuberculosis (TB) in patients. With the increasing resolution of molecular biology technologies, it is becoming apparent that antibiotic treatment can perturb the homeostasis of the host microbiome. For example, dysbiosis of the gut microbiota has been associated with an increased risk of the development of asthma, obesity and diabetes.
Source: Tuberculosis - Category: Respiratory Medicine Authors: Ronan F. O'Toole, Sanjay S. Gautam Tags: Review Source Type: research
More News: Asthma | Biology | Chemotherapy | Diabetes | Eating Disorders & Weight Management | Endocrinology | Molecular Biology | Obesity | Respiratory Medicine | Tuberculosis